# Humanin (Mitochondria-Derived Peptide)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 5 (Preclinical + observational human data)
**Risk Profile:** LOW (theoretical anti-apoptotic concern)
**FDA Status:** Research compound

---

## What Is This?

Humanin is a longevity peptide produced by your mitochondria (the energy factories in your cells). Here's what makes it fascinating: **centenarians (people over 100) have HIGHER humanin levels than younger elderly people** — and their children inherit elevated levels too. Humanin protects cells from dying, improves insulin sensitivity, and shows strong neuroprotection in Alzheimer's models. However, it's still in research phase with no established human protocols.

---

## Categories

`Longevity` · `Cognitive` · `Metabolic / Fat Loss`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| Mitochondria | The "power plants" inside cells that generate energy |
| MT-RNR2 | The mitochondrial gene that encodes humanin |
| Anti-apoptotic | Prevents programmed cell death |
| Bax, Caspase | Proteins involved in cell death pathways |
| STAT3 | A signalling protein that promotes cell survival |
| Amyloid-beta | The toxic protein that accumulates in Alzheimer's disease |
| HNG / S14G-HN | A synthetic analog of humanin that is 1000x more potent |
| MDP | Mitochondria-Derived Peptide — the family humanin belongs to |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Length | 24 amino acids |
| Molecular Weight | ~2,687 Da |
| Encoding | Mitochondrial DNA (MT-RNR2) |
| Half-life | Minutes |
| Receptors | FPRL1, CNTFR complex, IGFBP-3 |
| Discovery | 2001 (Hashimoto lab) |

---

## Why Humanin Matters for Longevity

The correlation between humanin and exceptional longevity provides one of the most compelling observational datasets in aging biology. Most age-related biomarkers decline monotonically with age — the older you get, the worse they get. Humanin breaks this pattern in centenarians.

| Age Group | Relative Humanin |
|-----------|------------------|
| Young adults | Baseline |
| Middle age | ~70-80% |
| Elderly | ~50-60% |
| **Centenarians** | **Above baseline** |

By middle age, humanin levels have dropped to 70-80% of youthful values. By conventional old age, they've fallen to 50-60%. This decline parallels metabolic deterioration, increased apoptosis, and cellular stress vulnerability. But centenarians — individuals who've lived beyond 100 years — show humanin levels that exceed even young adult baselines.

This isn't survivor bias. The children of centenarians also show elevated humanin compared to age-matched controls, suggesting genetic or epigenetic inheritance of this longevity advantage. High humanin appears to be both marker and mechanism of exceptional longevity — a rare example where correlation strongly suggests causation.

---

## Mechanism of Action

Humanin functions through multiple receptor systems, creating redundant protective pathways that resist cellular stress, metabolic dysfunction, and age-related damage.

The anti-apoptotic pathway provides the best-characterized mechanism. Humanin inhibits Bax translocation to mitochondria, preventing mitochondrial outer membrane permeabilization — the point of no return in the intrinsic apoptosis pathway. It blocks caspase activation, preventing the proteolytic cascade that executes cell death. Through STAT3 activation, it promotes cellular survival signaling and stress resistance.

This anti-apoptotic function has obvious implications for aging. Cells that should die from accumulated damage surviving inappropriately could contribute to cancer or senescent cell accumulation. But cells dying prematurely from stress that could be survived contributes to tissue dysfunction and age-related frailty. The balance matters — and humanin appears to shift it toward survival of repairable damage while maintaining elimination of irreparable cells through mechanisms not fully characterized.

The metabolic effects operate through improved insulin sensitivity and glucose homeostasis. Humanin enhances glucose tolerance in animal models, suggesting potential for metabolic dysfunction treatment. The mechanism appears to involve direct insulin receptor pathway modulation and improved mitochondrial function, creating a positive feedback loop where better mitochondrial health produces more humanin, which further improves metabolic function.

Neuroprotection represents perhaps the most therapeutically promising effect. Humanin protects neurons against amyloid-beta toxicity — the pathological hallmark of Alzheimer's disease. In cell culture and animal models, humanin prevents amyloid-beta-induced cell death, reduces oxidative stress, and maintains synaptic function. This positions humanin or its analogs as potential Alzheimer's therapeutics, though human clinical trials remain absent.

Cardiovascular protection emerged in ischemia-reperfusion models. When tissue is deprived of oxygen and then reperfused, the restoration of blood flow paradoxically causes additional damage through oxidative stress and inflammatory signaling. Humanin administration before or during reperfusion reduces this injury, suggesting potential for myocardial infarction or stroke treatment.

---

## Clinical Evidence

The evidence base for humanin reflects a compound with compelling observational data, strong mechanistic understanding, but no path yet to clinical translation.

### Human Observational Data (Strong)

The centenarian correlation stands as the most powerful human evidence. Higher circulating humanin correlates with exceptional longevity, with levels declining approximately 50% from young adulthood to conventional old age. Centenarians reverse this decline, showing levels above youthful baseline. Their offspring inherit this elevation, establishing familial clustering of the longevity biomarker.

Metabolic health correlations extend the observational data. Lower humanin associates with obesity, insulin resistance, and metabolic syndrome. Whether low humanin causes metabolic dysfunction or metabolic dysfunction suppresses humanin production remains unclear — likely the relationship is bidirectional, creating a vicious cycle in metabolic disease.

### Preclinical Data

Animal studies demonstrate benefits across multiple systems. In Alzheimer's models, humanin protects against amyloid-beta toxicity, preserves cognitive function, and reduces neurodegeneration. In diabetes models, humanin improves glucose tolerance and insulin sensitivity. In cardiovascular ischemia-reperfusion models, humanin reduces infarct size and preserves tissue function. In obesity models, humanin reverses metabolic dysfunction.

These effects consistently emerge across models and laboratories, establishing mechanistic proof-of-concept. What's missing: human intervention trials demonstrating that exogenous humanin administration produces clinically meaningful benefits with acceptable safety profiles.

---

## Humanin Analogs

The pharmacokinetics of native humanin create therapeutic challenges. With a half-life measured in minutes, maintaining therapeutic levels would require continuous infusion or frequent dosing — impractical for chronic conditions.

This drove development of synthetic analogs with enhanced potency and stability:

| Analog | Modification | Potency |
|--------|--------------|---------|
| HNG / S14G-HN | Gly→Ser at position 14 | **1000x more potent** |
| Colivelin | Hybrid with ADNF | Enhanced neuroprotection |

HNG (S14G-Humanin) represents the most extensively studied analog. The single amino acid substitution increases potency roughly 1000-fold, allowing effective dosing at much lower concentrations. Critically, most dramatic preclinical effects come from HNG studies, not native humanin. Results from HNG experiments should not be assumed to apply to native humanin at equivalent doses — the required doses differ by orders of magnitude.

If sourcing humanin peptides, verification of whether the product is native humanin or HNG becomes essential. The expected effects and appropriate doses differ substantially. Many underground suppliers may not clearly distinguish these forms, creating potential for underdosing (if HNG doses are used with native humanin) or overdosing (if native humanin doses are used with HNG).

Colivelin represents a hybrid molecule combining humanin with ADNF (activity-dependent neurotrophic factor), creating enhanced neuroprotective effects beyond either peptide alone. This remains in research development with no general availability.

---

## Current Status: NOT Ready for General Use

Despite compelling observational data and mechanistic promise, humanin sits firmly in the research phase rather than practical application phase.

### Why Caution

**No established human dosing protocols exist.** The centenarian data establishes correlation; it doesn't tell us what dose of exogenous humanin would produce benefit, what administration route works, or what duration of treatment is needed.

**Short half-life creates pharmacokinetic challenges.** Minutes-long circulating half-life means frequent dosing or continuous infusion — feasible in research settings, impractical for outpatient use. Even HNG's improved potency may not overcome the fundamental clearance issue.

**Quality control concerns plague research peptides.** Without pharmaceutical manufacturing standards, verification of peptide identity, purity, and potency becomes difficult. The native humanin vs HNG distinction adds complexity — if the supplier doesn't clearly specify which form they're providing, proper dosing becomes impossible.

**Anti-apoptotic mechanisms raise theoretical cancer concerns.** Blocking programmed cell death could allow damaged cells with oncogenic mutations to survive when they should be eliminated. No evidence suggests humanin increases cancer risk — but the mechanism creates theoretical concern requiring long-term safety data before widespread use.

**Limited to research settings means lack of clinical infrastructure.** No standardized protocols exist for patient selection, dosing titration, monitoring, or management of adverse effects. Early adopters would be experimenting without established safety guardrails.

---

## Use Cases by Goal

All use cases below remain theoretical, supported by mechanism and preclinical data but lacking human intervention trials.

### Neuroprotection / Cognitive Decline

The strongest preclinical signal points toward Alzheimer's disease prevention or treatment. Amyloid-beta protection, preservation of synaptic function, and reduction of neurodegeneration in animal models create mechanistic rationale. However, the path from mouse Alzheimer's models to human clinical benefit is littered with failed compounds. Humanin or HNG would need to traverse Phase I-III clinical trials before neuroprotective use could be recommended.

Potential: High (based on mechanism)
Status: Research only
Timeline to availability: Years, if development proceeds

### Metabolic Support

Improved insulin sensitivity and glucose tolerance in preclinical models suggest benefit for metabolic dysfunction. The observational correlation between low humanin and metabolic disease supports this potential. But again, no human dosing studies establish efficacy or safety.

Potential: Moderate (mechanistic support exists)
Status: Research only
Alternative approaches: Established treatments for metabolic dysfunction (metformin, GLP-1 agonists) with proven efficacy and safety profiles remain first-line

### Cardiovascular Protection

Ischemia-reperfusion protection in animal models suggests potential for myocardial infarction or stroke treatment. The acute nature of these indications might make the short half-life less problematic — administration during the event or immediately after could provide benefit without requiring chronic dosing.

Potential: High (mechanism suits acute intervention)
Status: Research only
Development pathway: Would require acute-care clinical trials in cardiovascular centers

### General Anti-Aging

The centenarian correlation provides the most compelling human data. If elevated humanin contributes to exceptional longevity rather than merely marking it, restoration of youthful humanin levels in those showing age-related decline could extend healthspan.

This remains the most speculative use case. Observational correlation, even strong correlation across multiple studies, doesn't prove that exogenous supplementation produces benefit. The children-of-centenarians data suggests genetic or lifelong elevation matters; whether pharmaceutical restoration in late life provides similar benefit remains entirely unproven.

Evidence: Observational correlation is strong
Status: Research only
Risk-benefit: Unclear without intervention data

---

## Supporting Endogenous Humanin (Alternative)

Given that exogenous humanin administration lacks established protocols and safety data, supporting endogenous production represents a more practical approach using validated interventions.

| Strategy | Evidence |
|----------|----------|
| Exercise | Increases humanin production |
| Mitochondrial support | CoQ10, NAD+ precursors |
| Caloric restriction | May increase levels |
| Avoiding mitochondrial toxins | Preserves production |

Exercise stands as the most established intervention for increasing humanin. Physical activity triggers mitochondrial adaptations including increased humanin production, creating a mechanistic link between exercise's metabolic benefits and this mitochondrial peptide.

Mitochondrial support through CoQ10 or NAD+ precursors (NMN, NR) may enhance the mitochondrial health that drives humanin production. While direct evidence linking these supplements to humanin elevation in humans remains limited, the mechanistic rationale is sound.

Caloric restriction increases lifespan across species and may increase humanin levels, though human data is sparse. Avoiding mitochondrial toxins — chronic alcohol, certain pharmaceuticals, environmental toxins — preserves the mitochondrial function necessary for humanin production.

These strategies lack the theoretical potency of direct humanin administration but offer established safety profiles and proven health benefits independent of humanin effects.

---

## Dosing (Research Context Only)

### Preclinical Doses

| Model | Dose | Route |
|-------|------|-------|
| Mice | 0.5-4 mg/kg | IP, IV, SC |
| Cells | nM-μM range | In vitro |

**No established human doses exist.**

Extrapolating from animal studies using allometric scaling might suggest human doses in the range of 0.05-0.4 mg/kg, or 3.5-28 mg for a 70 kg adult. However, this assumes linear scaling of pharmacokinetics and pharmacodynamics between species — an assumption frequently violated in peptide therapeutics. The short half-life compounds uncertainty about dosing frequency required to maintain therapeutic levels.

For HNG, doses would be roughly 1000-fold lower due to enhanced potency. The distinction between native humanin and HNG becomes critical for any dosing discussion.

---

## Risk Assessment

The safety profile of humanin appears favorable based on limited available data, but the absence of human intervention trials means this assessment carries substantial uncertainty.

| Parameter | Assessment |
|-----------|------------|
| Acute toxicity | None in models |
| Endogenous peptide | Natural origin |
| Anti-apoptotic | Theoretical cancer concern |
| Long-term | Unknown |

Acute toxicity appears absent in animal studies across the dose ranges tested. As an endogenous peptide produced naturally by human mitochondria, humanin lacks the foreign sequence concerns that might trigger immune responses or unexpected toxicities.

The anti-apoptotic mechanism creates theoretical cancer concern. Preventing programmed cell death could allow survival of cells with oncogenic mutations. However, humanin's effects appear context-dependent — protecting healthy cells from inappropriate apoptosis while maintaining elimination of irreparably damaged cells through mechanisms not fully understood. No cancer signal has emerged in animal studies, but long-term human data would be needed to definitively assess this risk.

Long-term safety in humans remains unknown. The centenarian data suggests that lifelong high endogenous humanin is not merely safe but correlates with exceptional longevity. Whether pharmacological elevation produces the same effect profile remains untested.

### Contraindications

- Active malignancy (anti-apoptotic caution)
- Pregnancy/breastfeeding (no data)

The malignancy contraindication stems from mechanistic concern rather than demonstrated harm. Until data clarifies whether humanin promotes, inhibits, or has no effect on established tumors, avoiding use in active cancer represents the prudent approach.

---

## The MDP Family

Humanin belongs to a family of mitochondria-derived peptides that regulate cellular function through intercellular signaling:

| Peptide | Primary Effect |
|---------|----------------|
| **Humanin** | Cytoprotection, anti-apoptosis |
| **MOTS-c** | Metabolic regulation (covered separately) |
| SHLPs 1-6 | Various (recently discovered) |

The discovery that mitochondria produce peptide hormones that regulate cellular and systemic function represents a paradigm shift in cell biology. Mitochondria aren't just energy factories but endocrine organs within the cell, producing signals that coordinate metabolic function, stress responses, and cellular survival.

The recently discovered SHLPs (small humanin-like peptides) 1-6 remain largely uncharacterized. Early data suggests diverse functions across the family, but practical applications await further research.

---

## Limitations

1. **Research stage only** - No clinical protocols
2. **Pharmacokinetic challenges** - Short half-life
3. **Quality concerns** - Variable peptide quality
4. **Anti-apoptotic mechanism** - Cancer concern
5. **Better alternatives** currently more practical

The honest assessment: humanin represents a fascinating research compound with compelling observational data and strong mechanistic rationale. But the path to practical use requires human intervention trials establishing efficacy, optimal dosing, safety parameters, and patient selection criteria. Until that data exists, supporting endogenous production through exercise and mitochondrial health represents the more practical approach.

For those seeking neuroprotection, metabolic support, or longevity benefits, established interventions with proven efficacy and safety profiles remain first-line. Humanin may eventually join that list — but it's not there yet.

---

## References

1. Hashimoto Y, et al. A rescue factor abolishing neuronal death by Alzheimer's genes. Proc Natl Acad Sci USA. 2001.
2. Muzumdar RH, et al. Humanin: a central regulator of peripheral insulin action. PLoS One. 2009.
3. Yen K, et al. Humanin is a regulator of lifespan and healthspan. Aging. 2020.
4. Kim SJ, et al. Mitochondrial-derived peptides as regulators of metabolism. J Physiol. 2017.
